TARA Biosystems
Developer of an AI-driven, human-data-focused drug discovery engine that integrates large-scale de-identified patient data, computational modeling, wet-lab chemistry, and engineered human tissue models to accelerate target discovery, small-molecule design, and preclinical candidate advancement. Publishes and applies standardized 3D engineered cardiac tissue assays for device and pharmacology testing and translational validation.
Industries
Nr. of Employees
small (1-50)
Products
AI-enabled closed-loop drug discovery engine
An integrated discovery engine that combines large-scale human data, machine learning models, wet-lab chemistry, and engineered human tissue testing to iterate from target discovery to preclinical candidate selection.
Standardized 3D engineered cardiac tissue assay
A standardized protocol and assay set for matured hiPSC-derived 3D cardiac tissues to measure contractile force, kinetics, and calcium handling under pharmacological and electrical stimulation conditions for preclinical testing.
AI-enabled closed-loop drug discovery engine
An integrated discovery engine that combines large-scale human data, machine learning models, wet-lab chemistry, and engineered human tissue testing to iterate from target discovery to preclinical candidate selection.
Standardized 3D engineered cardiac tissue assay
A standardized protocol and assay set for matured hiPSC-derived 3D cardiac tissues to measure contractile force, kinetics, and calcium handling under pharmacological and electrical stimulation conditions for preclinical testing.
Services
Provision of computational modeling, data integration, and predictive analytics to identify targets, design molecules, and inform program decisions via collaborative engagements.
In vitro evaluation and optimization of electrical device signals and pharmacological agents using matured 3D engineered cardiac tissues with contractility, calcium, and molecular readouts; includes translational comparisons with ex vivo and in vivo models where applicable.
Provision of computational modeling, data integration, and predictive analytics to identify targets, design molecules, and inform program decisions via collaborative engagements.
In vitro evaluation and optimization of electrical device signals and pharmacological agents using matured 3D engineered cardiac tissues with contractility, calcium, and molecular readouts; includes translational comparisons with ex vivo and in vivo models where applicable.
Expertise Areas
- AI-driven drug discovery
- Human-centric data integration and causal biology
- Target discovery and prioritization using genetics and network biology
- Computational small-molecule design and large-scale virtual screening
Key Technologies
- Machine learning and artificial intelligence
- Closed-loop active learning
- Large-scale computational small-molecule screening
- DNA-encoded library integration
News & Updates
Strategic collaboration leveraging an AI-enabled human causal biology platform to identify targets and generate preclinical compounds for Parkinson’s disease.
Valo Health Awarded Grant from The Michael J. Fox Foundation to Advance Parkinson’s Disease Research
Award to participate in a consortium studying NOD2 and related pathways using genetics, multi-omics, and network biology to clarify causal relationships relevant to Parkinson’s disease.
Announcement of an advanceable preclinical candidate discovered through an integrated target-to-candidate offering combining computational platforms with preclinical lead-generation workflows.
Publication describing use of 3D engineered human cardiac tissues to quantify effects of cardiac contractility modulation electrical signals on contractile force, demonstrating parameter-dependent responses not observed in standard 2D monolayer models.
Publication reporting that application of C-type natriuretic peptide produced dose-dependent positive inotropic and lusitropic effects in matured 3D human engineered cardiac tissues and showed translational concordance with ex vivo and in vivo rat models; includes hemodynamic analyses demonstrating increases in dP/dt and improvements in diastolic parameters without changes in systemic blood pressure.
Publication describing electrical stimulation protocols applied to engineered muscle tissues and resulting functional and phenotypic changes, demonstrating experimental protocol development for engineered tissue platforms.
Strategic collaboration leveraging an AI-enabled human causal biology platform to identify targets and generate preclinical compounds for Parkinson’s disease.
Valo Health Awarded Grant from The Michael J. Fox Foundation to Advance Parkinson’s Disease Research
Award to participate in a consortium studying NOD2 and related pathways using genetics, multi-omics, and network biology to clarify causal relationships relevant to Parkinson’s disease.
Announcement of an advanceable preclinical candidate discovered through an integrated target-to-candidate offering combining computational platforms with preclinical lead-generation workflows.
Publication describing use of 3D engineered human cardiac tissues to quantify effects of cardiac contractility modulation electrical signals on contractile force, demonstrating parameter-dependent responses not observed in standard 2D monolayer models.
Publication reporting that application of C-type natriuretic peptide produced dose-dependent positive inotropic and lusitropic effects in matured 3D human engineered cardiac tissues and showed translational concordance with ex vivo and in vivo rat models; includes hemodynamic analyses demonstrating increases in dP/dt and improvements in diastolic parameters without changes in systemic blood pressure.
Publication describing electrical stimulation protocols applied to engineered muscle tissues and resulting functional and phenotypic changes, demonstrating experimental protocol development for engineered tissue platforms.